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Abstract Chromoblastomycosis, a chronic fungal
infection of skin and subcutaneous tissue caused by
dematiaceous fungi, is associated with low cure and high
relapse rates. Among all factors affecting clinical
outcome, etiological agents have an important position.
In southern China, Fonsecaea pedrosoi and Fonsecaea
monophora are main causative agents causing Chromo-
blastomycosis. We treated one case of chromoblastomy-
cosis by photodynamic therapy (PDT) of
5-aminolevulinic acid (ALA) irradiation combined with
terbinafine 250 mg a day. The lesions were improved
after two sessions of ALA-PDT treatment, each including
nine times, at an interval of 1 week, combined with
terbinafine 250 mg/day oral, and clinical improvement
could be observed. In the following study, based on the
clinical treatment, the effect of PDT and antifungal drugs
on this isolate was detected in vitro. It showed sensitivity
to terbinafine, itraconazole or voriconazole, and PDT
inhibited the growth. Both the clinic and experiments
in vitro confirm the good outcome of ALA-PDT applied
in the inhibition of F. monophora. It demonstrated that
combination of antifungal drugs with ALA-PDT arises as
a promising alternative method for the treatment of these
refractory cases of chromoblastomycosis.
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Introduction
Chromoblastomycosis, one of the most frequently
encountered subcutaneous mycosis in tropical and
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subtropical regions, is characterized by slowly
expanding skin lesions. Usually, it is caused by
traumatic inoculation of a specific group of dematia-
ceous fungi and associated with low cure and high
relapse rates [1, 2]. Several species of pathogens are
involved in the disease etiology, including Cladophi-
alophora carrionii, Fonsecaea pedrosoi, Fonsecaea
monophora, Fonsecaea nubica and Rhinocladiella
aquaspersa [3]. In southern China, F. pedrosoi and F.
monophora are the most common causes [4], while
other fungi, such as F. nubica and Phialophora
aquaspersa, are less common [5, 6].
Due to its recalcitrant nature, treatment of the disease
is still a challenge [7]. Strains of F. pedrosoi can be
resistant to many antifungal drugs, and infections can be
extremely difficult to eradicate [8, 9]. Conversely, the
treatment of cases caused by F. monophora is relatively
easier [10, 11]. More effective methods have been
employed for inhibiting the pathogen’s activity, like
photodynamic therapy (PDT). PDT is a minimally
invasive approach, in which photosensitizer is activated
by exposure to low-intensity harmless visible light. The
activation of photosensitizer results in the production of
reactive oxygen species and other reactive molecules,
which, in the biological site, leads to the damage of
targets. It has been developed to combat cancerous
lesions, including infectious diseases. A wide range of
microorganisms has been demonstrated susceptibility to
antimicrobial PDT [12, 13]. This treatment may be
considered an alternative for the management of fungal
infections [14]. Antifungal PDT has been successfully
employed against Candida species [15], dermatophytes
[16], A. fumigatus [17] and F. monophora [3].
In this study, the clinical effect of PDT on
chromoblastomycosis and the antifungal activity of
in vitro were evaluated. We describe one refractory
case treated by PDT combined with terbinafine. The
clinical effect is positive, denoting the efficiency of
PDT against chromoblastomycosis. Considering that
the majority of the published works are focused on
in vitro trials, these clinical tests can be considered as a
relevant source of information about antifungal PDT.
Case Report
A 50-year-old male farmer residing in Guangzhou,
China, presented to our outpatient clinic on March 29,
2011. He complained of an itchy erythematous plaque
surrounded with veracious hyperplasia on the right
ankle (Fig. 1a). The lesion started 30 years ago after
local trauma and enlarged gradually. The patient had
visited another hospital, and a clinical diagnosis of
deep mycosis (without isolation of pathogen) was
made. Before he came to our hospital, itraconazole and
fluconazole had been employed for a long time (more
than 1 year). In our hospital, both examination of
potassium hydroxide mounts (Fig. 2a) and histopa-
thology revealed dematiaceous muriform cells
(Fig. 2b, c) and the diagnosis of chromoblastomycosis
was supported. Based on mycological study and DNA
sequencing, the etiological agent was identified as F.
monophora. The family history or past medical history
was unremarkable. Underlying diseases or immuno-
compromised conditions were not present in this
patient. In the treatment, terbinafine 500 mg/day oral
was administered for 4 weeks, but no significant
improvement was observed (Fig. 1b). Then, PDT of
ALA (concentration of 20 %, duration time of 4 h)
irradiation was adopted combined with terbinafine
250 mg/day oral, from April 26, 2011, to July 7, 2011,
totally for nine times, at an interval of 1 week, but not
improved previously. From September 1, 2011, to
January 13, 2012, he received this therapy for another
nine times, at an interval of 1 week, and combined
with terbinafine 250 mg/day oral. In between, terbi-
nafine 250 mg/day oral was given. The lesions were
obviously improved clinically, and fungal examina-
tion was negative (Fig. 1c). And there was no new
lesions developed after ALA-PDT treatment cessation
(Fig. 1d). One year later, the plaque disappeared and
just left some hypopigmentation.
Materials and Methods
Identification of Isolate
KOH examination of scales from the lesion and
histopathology of a biopsy specimen were made.
Then, macroscopic and slide culture of the isolate was
done [3, 10, 21].
DNA was extracted using 6 % InStaGeneTM Matrix
(Bio-Rad, Hercules, CA, USA). Ribosomal
DNA ITS domains were amplified in a Biometra
T-Gradient Thermoblock (Whatman Biometra,
Goettingen, Germany) using primers ITS-5 (50-
GGAAGTAAAAGTCGTAACAAGG-30) and ITS-4
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(50-TCCTCCGCTTATTGATATGC-30). PCR was car-
ried out at 94 C for 5 min, followed by 30 cycles at
94 C for 60 s, annealing at 55 C for 90 s and an
extension at 72 C for 90 s. The reaction continued at
72 C for 10 min. The DNA fragments were sequenced
with an ABI PRISM 3100 sequencer (Applied Biosys-
tems, Foster City, CA, USA).
Antifungal Susceptibility Testing
The clinical isolate was submitted to antifungal
susceptibility testing according to CLSI guidelines
(M38-A document) as previously described [3, 10],
and the MICS of antifungal combination was accord-
ing to previously described [3, 10]. Itraconazole
(Xian-Janssen Pharmaceutical Ltd. Xi’an, China),
terbinafine (Beijing Novartis Pharmaceutical Ltd.,
Beijing, China) and voriconazole (Sigma, USA) were
dissolved in 100 % DMSO as stock solution
(3,200 lg/mL). Drugs were diluted to obtain the final
concentrations, with itraconazole and voriconazole
from 0.008 to 8 lg/mL and terbinafine from 0.008 to
0.5 lg/mL. The isolates were subcultured, and the
spores of the colonies were collected and adjusted with
saline to achieve an inoculum concentration of
106 conidia/mL. Each suspension was diluted
1:50–100 with RPMI 1640 to obtain the final test
inoculum (0.4–5 9 104 conidia/mL). Suspension of
conidia of each the tested strains was cultivated on
RPMI 1640 medium for 7 days at 35 C. Candida
parapsilosis ATCC22019 (CBS604), obtained from
Centraalbureau voor Schimmelcultures (CBS, the
Netherlands), was used as a quality control. The final
test inoculum concentration was 0.5–2.5 9 103 -
conidia/mL.
Antifungal Effect of ALA-PDT in F. monophora
In the present investigations, the F. monophora
isolated from the patient was used in all experiments.
The first culture of F. monophora (master plates) was
carried out on Kimmig-Agar-Plates (Merck, Darms-
tadt, Germany) for 3–4 weeks at room temperature in
the dark. Finally, liquid cultures of F. monophora were
prepared by inoculation of Sabouraud glucose (2 %)
broth (Heipha Diagnostika, Heidelberg, Germany)
with fungi from master plates. Liquid cultures were
continuously shaken at 50 rpm on a shaker Promax
2020 (Heidolph, Schwabach, Germany) to achieve
dynamic availability of ALA for fungal growth.
Fig. 1 Clinical aspect of chromoblastomycosis lesions of
patient before and after therapy. There is an itchy erythematous
plaque surrounded with veracious hyperplasia on the right ankle
of the second patient (a), the clinical is not improved after took
ten years’ antifungal drugs (b), and the lesion is obviously
improved clinically after ALA-PDT irradiation combined with
terbinafine (c, d)
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ALA was kindly provided by Schering AG (Berlin,
Germany). Two stock solutions of ALA with concen-
trations of 3.33 M (stock solution I) and 33.3 M (stock
solution II) were prepared. Prior to use, both solutions
were sterile-filtered (0.2 lm, Schleicher & Schuell,
Dassel, Germany) and added to the growth media at
the appropriate concentration.
Photo-Inactivity Effect of ALA-PDT
in F. monophora In Vitro
A Zeiss KL 2500 LED was used for all irradiation
experiments, and the wavelength was 635 nm. The
fluency rate of the illuminator was 36.8 mW/cm2.
White light was applied (unfiltered) in these examin-
ations. The distance from the fiber optic to the surface
of the plates was 5 cm, in order to minimize the non-
uniformity of the light output across the irradiated
area. Plates with F. monophora were exposed to a
treatment equivalent to 10 J. After 7 days of further
incubation at room temperature, plates of F. mono-
phora were evaluated for photo-killing effects of
ALA-PDT, and CFU counting was made. All tests
were made in triplicate.
Results
Identification of Isolate
KOH wet mount of the sample from the lesion showed
muriform cells (dark brown large cells; Fig. 2a).
Histopathology of a biopsy specimen revealed mild
acanthosis of the epidermis and granulomatous
Fig. 2 Manifestations of KOH examination of scales, histopa-
thological examination of biopsy and fungal culture from
patient. KOH wet mount of the sample from the lesion, showing
muriform cells (9400) (a); muriform cells in histopathological
examination of biopsy (hematoxylin–eosin stain) (b 9100;
c 9400); macroscopic appearance of a Fonsecaea colony (d);
microculture of F. monophora (9400) (e)
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inflammation around the entire dermis (Fig. 2b, c).
Muriform cells were observed in micro-abscess or
giant cells (Fig. 2e).
DNA Sequence Analyses
The sequence showed 99 % homology with type strain
SUMS 0246 in GenBank (EF 513768.1) and was
confirmed as F. monophora. The sequences data of the
isolates were deposited in the GenBank with accession
numbers JN629041 and JN629042.
Antifungal Susceptibility Testing
The clinical isolates were submitted to antifungal
susceptibility testing, and the results are shown in
Table 1. Terbinafine, itraconazole and voriconazole
all demonstrated considerable efficacy against the
clinical isolate from this patient. The minimal inhib-
itory concentrations (MICs) were 0.125, 1 and 0.5 lg/
ml, respectively; the fractional inhibitory concentra-
tion index (FICI) was 0.75 and 0.75, respectively.
Antifungal Effect of ALA-PDT in F. monophora
After 7 days of further incubation at room tempera-
ture, plates of F. monophora were evaluated for photo-
killing effect of ALA-PDT by CFU quantification
(Fig. 3). In this experiment, we could clearly demon-
strate the growth-inhibiting effect of ALA-PDT; both
a reduced number of colonies on the irradiated plates
and the reduced diameters of single fungal colonies
could be observed.
Discussion
The chromoblastomycosis case was caused by F.
monophora, which was first identified by De Hoog
[18]. In various antifungal drugs, itraconazole and
terbinafine are considered to be effective. The patient
here was initially treated with terbinafine or itraco-
nazole or the combination, but without any good
response. When PDT was employed, the lesions were
improved significantly.
Topical PDT, the combination of a sensitizing drug
and visible light causing destruction of selected cells,
was firstly employed in oncological field [12]. Now, it
is a well-established treatment for a variety of
malignant skin tumors and inflammatory diseases,
including non-melanoma skin cancer, actinic kerato-
sis, acne vulgaris, photo-rejuvenation and hid adenitis
supportive [13]. Moreover, it has been extended to
antimicrobial chemotherapy. PDT in treating the
infection caused by Candida species [15], Dermato-
phytes [16], Aspergillus [17] and Fonsecaea [11, 17]
has been reported with promising results. More related
investigation has been developed both in vitro and
in vivo [14]. In the cases here, although the complete
healing in clinical and mycological was not achieved,
the lesions were improved greatly. The result of
in vitro studies is compatible with the clinical
response, which showed the growth-inhibiting effect
of ALA-PDT on F. monophora.
The isolate of F. monophora was assayed for
antifungal susceptibility. Terbinafine, itraconazole
and voriconazole all showed good sensitivity for the
isolate from this case, with the MICs being 0.125, 1
and 0.5 lg/ml, respectively. This also suggested that
the determination of in vitro susceptibility profiles
may be useful to identify intrinsic microbiologic
resistance to antifungal drugs, but does not predict the
clinical response [19, 20]. Patients’ status is also the
important factors for the treatment effect. Our previ-
ous studies found that there was a synergistic effect of
terbinafine and itraconazole on clinical isolates of F.
monophora [21, 22].
Although chromoblastomycosis is associated with
low cure and high relapse rates [2], many cases caused
by F. monophora were successfully treated.
Table 1 The MIC and FICI of ITZ/TBF and VOR/TBF against the isolate
The isolation Drugs MIC (lg/ml) MICs of the combination FICI
ITZ VOR TBF ITZ VOR TBF
F. monophora ITZ/TBF 1 – 0.125 0.25 – 0.0625 0.75
VOR/TBF – 0.5 0.125 – 0.125 0.0625 0.75
MIC minimal inhibitory concentration, FICI fractional inhibitory concentration index, ITZ itraconazole, TBF terbinafine, VOR
voriconazole
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Terbinafine and PDT are promising methods in
treating refractory cases of chromoblastomycosis. It
was reported that miconazole could be used to increase
the efficacy of PDT against C. albicans, and its
mechanism of action is likely to be multi-factorial
[23]. Terbinafine could also increase the efficacy of
PDT against F. monophora, but this should be
confirmed in vitro.
In vitro PDT against F. pedrosoi and Cladophialo-
phora carrionii was reported [24], and this study was
also performed to investigate the possibility, as to
whether F. monophora can be inactivated by ALA-
PDT in vitro. F. monophora was treated with ALA and
irradiated to obtain photodynamic inactivation of this
fungus. We clearly demonstrated the growth-inhibit-
ing effect of ALA-PDT. As a result, both a reduced
number of colonies and the reduced diameters of
single fungal colonies on the irradiated plates could be
observed.
In order to bypass these limiting factors, ALA
should be esterified to enhance the uptake and
conversion of ALA by F. monophora. The results of
the irradiation experiments are encouraging, as it
showed that almost 50 % of the fungal growth could
Fig. 3 Antifungal effect of ALA-PDT in F. monophora. a 0 M
ALA, and without light irradiation; b 0.1 M ALA, and without
light irradiation; c 1.0 M ALA, and without light irradiation;
d 10.0 M ALA, and without light irradiation; e 100.0 M ALA,
and without light irradiation; f 0 M ALA, and with light
irradiation; g 0.1 M ALA, and with light irradiation; h 1.0 M
ALA, and with light irradiation; i 10.0 M ALA, and with light
irradiation; j 100.0 M ALA, and with light irradiation; and k the
statistics of the antifungal effect of ALA-PDT in F. monophora
(***p \ 0.01)
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be inhibited in vitro. Further experiments should be
performed to substantiate the growth-limiting proper-
ties of ALA-PDT to obtain a successful treatment of
chromoblastomycosis infection.
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